- Home
- WLK vs BBIO Comparison
WLK vs BBIO Comparison
Compare WLK & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WLK | BBIO |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 14.4B |
| IPO Year | 2004 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WLK | BBIO |
|---|---|---|
| Price | $74.21 | $74.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 20 |
| Target Price | ★ $88.00 | $75.75 |
| AVG Volume (30 Days) | 1.7M | ★ 2.0M |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,480,000,000.00 | $353,780,000.00 |
| Revenue This Year | N/A | $128.44 |
| Revenue Next Year | $3.18 | $76.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.46 |
| 52 Week Low | $56.33 | $25.34 |
| 52 Week High | $122.70 | $75.24 |
Technical Indicators
Market Signals| Indicator | WLK | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 68.19 |
| Support Level | $68.26 | $70.35 |
| Resistance Level | $70.34 | $75.10 |
| Average True Range (ATR) | 2.77 | 2.33 |
| MACD | 1.60 | -0.13 |
| Stochastic Oscillator | 93.33 | 98.77 |
Price Performance
Historical ComparisonAbout WLK Westlake Corporation
Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.